Senti taps tumor-homing MSCs for lead engineered immunotherapy

Why synthetic bio company Senti chose MSCs expressing IL-12 and IL-21 as its lead cancer program

While Senti’s first disclosed program, SENTI-101, doesn’t incorporate the sense-and-response circuits its scientific founders are known for, the company did use its synthetic biology toolbox to engineer over 60 types of mesenchymal stem cells secreting different combinations of immune mediators. It has landed on MSCs

Read the full 451 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE